Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.

PMID:
19706860
[PubMed - indexed for MEDLINE]
2.

Duration of androgen suppression in the treatment of prostate cancer.

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.

N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.

PMID:
19516032
[PubMed - indexed for MEDLINE]
Free Article
3.

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF.

J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.

PMID:
19506162
[PubMed - indexed for MEDLINE]
Free Article
4.

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.

PMID:
19047297
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.

PMID:
18980297
[PubMed - indexed for MEDLINE]
Free Article
6.

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU.

J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.

PMID:
18413638
[PubMed - indexed for MEDLINE]
Free Article
7.

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS.

Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.

PMID:
18348297
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.

Smith MR, Lee H, Fallon MA, Nathan DM.

Urology. 2008 Feb;71(2):318-22. doi: 10.1016/j.urology.2007.08.035.

PMID:
18308111
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.

PMID:
18243498
[PubMed - indexed for MEDLINE]
10.

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.

PMID:
18212313
[PubMed - indexed for MEDLINE]
11.

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV.

J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.

PMID:
18172188
[PubMed - indexed for MEDLINE]
Free Article
12.

Diagnosis and classification of diabetes mellitus.

American Diabetes Association.

Diabetes Care. 2008 Jan;31 Suppl 1:S55-60. doi: 10.2337/dc08-S055. No abstract available.

PMID:
18165338
[PubMed - indexed for MEDLINE]
13.

Standards of medical care in diabetes--2008.

American Diabetes Association.

Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012. No abstract available.

PMID:
18165335
[PubMed - indexed for MEDLINE]
14.

Rising PSA in nonmetastatic prostate cancer.

Moul JW, Bañez LL, Freedland SJ.

Oncology (Williston Park). 2007 Nov;21(12):1436-45; discussion 1449, 1452, 1454. Review.

PMID:
18077992
[PubMed - indexed for MEDLINE]
Free Article
15.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
[PubMed - indexed for MEDLINE]
Free Article
16.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

PMID:
17657815
[PubMed - indexed for MEDLINE]
Free Article
17.

Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW.

J Clin Oncol. 2007 Jun 10;25(17):2420-5.

PMID:
17557956
[PubMed - indexed for MEDLINE]
Free Article
18.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
[PubMed - indexed for MEDLINE]
Free Article
19.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

PMID:
16921050
[PubMed - indexed for MEDLINE]
Free Article
20.

AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute.

Circulation. 2006 May 16;113(19):2363-72. No abstract available. Erratum in: Circulation. 2006 Jun 6;113(22):e847.

PMID:
16702489
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk